Figure 2

Effect of alfacalcidol and risedronate, alone or in combination, on the bone resorption marker in OVX rats. Starting 12 weeks after OVX, drugs were administered orally to rats for 12 weeks. Urinary DPD excretion was measured as biochemical marker of bone resorption, as described in MATERIALS AND METHODS. Data for DPD are corrected for urinary CRE concentrations. Each value represents the mean ± SE (n = 7–8). *p < 0.05, **p < 0.01, ***p < 0.001 compared with the OVX-control group. Note that the combination therapy with ALF and RIS suppressed urinary DPD excretion more effectively than each drug alone. DPD: deoxypyridinoline, CRE: creatinine.